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Abstract
Background: Concomitant use of clarithromycin (CAM) and rifampicin (RFP) for the treatment of pulmonary
Mycobacterium avium complex (MAC) disease affects the systemic concentrations of both drugs due to
CYP3A4–related interactions. To date, however, there has been no report that investigates the long–term
relationship between the drug concentrations, CYP3A4 activity, and clinical outcomes. Our aim was to
investigate the time course of the drug levels in long–term treatment of subjects with pulmonary MAC
disease, and examine the correlation of these concentrations with CYP3A4 activity and clinical outcomes.
Methods: Urine and blood samples from nine outpatients with pulmonary MAC disease were collected on days 1, 15,
and 29 (for four subjects, sample collections were continued on days 57, 85, 113, 141, 169, 225, 281, 337, and 365).
Serum drug concentrations and urinary levels of endogenous cortisol (F) and 6 beta-hydroxycortisol (6βOHF), the
metabolite of F by CYP3A4, were measured, and evaluated 6βOHF/F ratio as a CYP3A4 activity marker. In addition, the
clinical outcomes of 4 subjects were evaluated based on examination of sputum cultures and chest images.
Results: The mean 6βOHF/F ratio increased from 2.63 ± 0.85 (n = 9) on the first day to 6.96 ± 1.35 on day 15 and
maintained a level more than double initial value thereafter. The serum CAM concentration decreased dramatically from
an initial 2.28 ± 0.61 μg/mL to 0.73 ± 0.23 μg/mL on day 15. In contrast, the serum concentration of 14-hydroxy-CAM
(M-5), the major metabolite of CAM, increased 2.4-fold by day 15. Thereafter, both CAM and M-5 concentrations remained
constant until day 365. The explanation for the low levels of serum CAM in pulmonary MAC disease patients is that
RFP-mediated CYP3A4 induction reached a maximum by day 15 and remained high thereafter. Sputum cultures of three
of four subjects converted to negative, but relapse occurred in all three cases.
Conclusions: Our study demonstrated that serum CAM concentrations in pulmonary MAC disease patients were
continuously low because of RFP-mediated CYP3A4 induction, which may be responsible for the unsatisfactory
clinical outcomes.
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Background
Mycobacterium avium complex (MAC) is the most com-
mon etiologic agent of lung disease caused by nontuber-
culous mycobacteria [1]. Because MAC is not susceptible
to antituberculous drugs, clarithromycin (CAM) is the key
drug for treatment of pulmonary MAC disease, and multi-
drug therapy with rifampicin (RFP) and ethambutol (EB)
is recommended to prevent the development of resistant
bacteria [2, 3].
RFP induces metabolic enzymes such as CYP3A4 and,
as a result, decreases the serum or plasma concentration
of concomitantly administered CAM and promotes its
metabolism to 14-hydroxy-CAM (M-5), which is less ef-
fective against MAC than the parent compound [4–6].
Yamamoto and colleagues [4] reported that the mean
plasma CAM concentration on the 8th day after RFP
addition decreased to 20 %. Taki and colleagues [5] dem-
onstrated that the mean serum CAM concentration
decreased to 15 % on the 3rd day after RFP addition.
Wallace and colleagues [6] reported that the plasma
CAM concentration decreased to 13 % when concomi-
tantly administered with RFP (mean medication period:
4.4 months). RFP-mediated enzyme induction begins
within 2–4 days after starting administration, reaches a
maximum within 6–10 days, and returns to preinduction
levels 2–3 weeks after stopping the administration of the
drug [7]. In contrast, administration of CAM increases
the serum or plasma concentrations of any concomi-
tantly administered drugs by inhibiting p-glycoprotein
and CYP3A4 [8, 9]. Previous reports have demonstrated
that the plasma concentration of RFP increased when
RFP was administered together with CAM [10]. In
humans, the main metabolic pathway of RFP is deacety-
lation to 25-desacetylrifampicin (DR) by arylacetamide
deacetylase [11].
When both RFP and CAM are used together to
treat pulmonary MAC, low serum CAM concentra-
tions may result in an unfavorable treatment outcome
and the emergence of resistant bacteria. In addition,
side effects such as liver damage, leukopenia, or
thrombocytopenia can occur when serum concentra-
tions of RFP rise. According to the current guidelines
provided by the American Thoracic Society, Japanese
Society for Tuberculosis (JSTB), and Japanese Respiratory
Society (JRS), the chemotherapeutic treatment period for
pulmonary nontuberculous mycobacteria (NTM) disease
is approximately one year after culture-negative conver-
sion [12, 13]. Previous studies investigating the serum or
plasma concentrations of CAM and RFP in patients
with pulmonary MAC disease were limited to short-
term studies focused on the early period of treatment,
around 1 week [4, 5], or examined results at only one
time point after long-term treatment [6]. Koh and col-
leagues [14] claimed that there was no association
between low plasma CAM concentrations in patients
with pulmonary MAC disease and treatment outcomes.
However, only one sample was collected for each pa-
tient in their study. Therefore, although the therapy
needed to be long term, it remained unclear whether
the exposure level to drugs was constant during the
therapy. Furthermore, there has been no report that
investigates the long-term relationship between drug
concentrations and CYP3A4 activity, together with an
examination of efficacy.
The present study was designed to monitor the long-
term time course of drug concentrations in the serum of
subjects with pulmonary MAC disease treated with RFP
and CAM. We also measured the urinary concentrations
of endogenous cortisol (F) and 6 beta-hydroxycortisol
(6βOHF), the metabolite of F by CYP3A4, and evaluated
the 6βOHF/F ratio as a marker of the activity of CYP3A4.
Furthermore, we evaluated the clinical outcomes of pa-
tients who continued this study for 1 year based on the
examination of sputum cultures and chest images.
Methods
Subjects
Nine outpatients diagnosed with pulmonary MAC disease
at the Chemotherapy research institute, Kaken hospital
(Kaken hospital) from 2012 to 2014 were enrolled in this
study. Patients under 20 years of age, over 80 years of age,
or with hepatic or renal dysfunction were excluded. All
patients were required to fulfill the JSTB and JRS criteria.
Doses of CAM, RFP, and EB were based on the recom-
mendations of both societies. Urine and blood samples
were collected on days 1, 15, 29 (for four subjects, sample
collections were continued on days 57, 85, 113, 141, 169,
225, 281, 337, and 365). Urine samples were collected on
the morning of the first day before a medical examination
and the subjects were administered the drugs after lunch
with blood collected two hours later. On days 15, 29, 57,
85, 113, 141, 169, 225, 281, 337, and 365, the subjects
took the drugs at home after breakfast and then two
hours later, urine and blood samples were collected
before a medical examination in the hospital. The urine
samples were collected at almost the same time as on the
first day. Serum and urine samples were frozen and stored
at –80 °C until analysis.
This study was conducted in compliance with the
ethical guidelines for clinical studies. It was approved
by the Ethical Review Committee at Tokyo University
of Science (approval and study number: 12001) and
Kaken hospital (approval and study number: 9) and
registered in the University hospital Medical Informa-
tion Network-Clinical Trial Registry (November 15,
2012, ID: UMIN000009343). All patients provided
written informed consent before entry into the study.
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Reagents
The internal standard roxithromycin, CAM, RFP, DR,
and F were purchased from Wako Pure Chemical Indus-
tries, Ltd. (Osaka, Japan), while 6βOHF and prednisol-
one, which served as an internal standard for analysis,
were purchased from SIGMA-Aldrich Japan Co. (Tokyo,
Japan). M-5 was kindly provided by Taisho Toyama
Pharmaceutical Co., Ltd. (Tokyo, Japan).
Measurement of serum drug concentrations and urinary
6βOHF and F concentrations
The serum concentrations of CAM, M-5, RFP, and DR
were measured using the liquid chromatography-tandem
mass spectrometry method described by Oswald et al.
[15], with modifications. The liquid chromatography-
tandem mass spectrometry system used consisted of an
LC-20 AD high-performance liquid chromatography
(HPLC) system (Shimadzu Co., Kyoto, Japan) coupled with
an API 3200 mass spectrometer (AB Sciex Japan, Ltd.,
Tokyo, Japan). The separations were performed on the
reverse phase column Atrantis T3 (5 μm, 2.1 × 150 mm,
Nihon Waters Co. Ltd., Tokyo, Japan) and using the solvent
mixtures (A) 10 mM ammonium acetate–acetonitrile
(20:80) and (B) 10 mM ammonium acetate-acetonitrile
(80:20) with the following gradient: 40 % B increased to
85 % B over 4 min, decreased to 40 % B over 1.25 min,
increased to 85 % B over 0.85 min, and equilibrated back to
40 % B over 0.9 min.
Urinary 6βOHF and F concentrations were measured
using the HPLC-UV method described by Hu et al. [16],
with modifications. The HPLC system used consisted of
an L-2130 pump and an L-2455 UV detector (HITACHI
High-Tech Science Co. Ltd., Tokyo, Japan). The detec-
tion wavelength was fixed 245 nm. The separations were
performed on the reverse phase column PEGASIL ODS
SP100 (5 μm, 4.6 × 250 mm, Senshu Scientific Co., Ltd.,
Tokyo, Japan), and using the solvent mixtures (A) aceto-
nitrile and (B) acetonitrile-water (17.5: 82.5), with the
gradient starting at 100 % B and decreasing to 63.6 % B
over 80 min.
Statistical analyses
The serum concentration for each drug and the ratio of
urinary 6βOHF/F are presented as the mean ± standard
error (SE). Data on day 15 were compared with each ini-
tial value using paired Student’s t-test during the initial
period of study (the day 1–29). The significance level for
each comparison was set as P <0.05. Serum RFP concen-
trations (mean ± SE) were plotted against the ratio of
urinary 6βOHF/F (mean ± SE) from the same time point
and the relationship between the values was examined
using the Pearson correlation coefficient. All statistical
analyses were performed using Excel 2010 (Microsoft
Co., Redmond, WA, USA).
Clinical outcomes
The clinical outcomes of four subjects who continued in
this study for 1 year were evaluated by examination of
sputum cultures and chest images at the indicated time
points. The cultures were scored as “– (negative)”, “1+”,
“2+”, “3+”, or “4+”. Culture negative conversion was
defined as three consecutive negative cultures; with the
time of conversion defined as the date of the first nega-
tive culture. The subjects were monitored and relapse was
recorded during the observation period (until day 365)
and post-observation period (after day 365), as the first
day of a positive culture after negative scores. Chest im-
ages were evaluated by a pulmonologist, and classified as
“Improved”, “Unchanged”, and “Worsened” compared to
the previous assessment.
CAM susceptibility test
CAM susceptibility tests were performed using the mini-
mum inhibitory concentration (MIC) method for 3 of
the 4 subjects who continued in this study for 1 year. If
sputum culture conversion was not achieved after
169 days, isolates from the last positive cultures col-
lected were tested. According to the JSTB and JRS
guidelines for chemotherapy of pulmonary nontubercu-
lous mycobacterial disease-2012 revised version [13],
strains with MIC of CAM (≦4 μg/mL) were considered
susceptible to CAM, while those with an MIC ≧32 μg/mL
were considered resistant. Values of 8–16 μg/mL were
considered intermediate.
Results
Subject characteristics and dosage
Subject characteristics and dosage are summarized in
Table 1. Etiologic agents were identified as M. avium in
seven subjects, M. intracellulare in one subject, and M.
avium-M. intracellulare overlapping in one subject. The
subject population comprised two male and seven fe-
male subjects. The averages of age and body weight
(mean ± SE) were 66.6 ± 2.4 years old and 50.7 ± 2.4 kg,
respectively. The daily dose of drugs consisted of CAM
600–800 mg, RFP 450–600 mg, and EB 500–750 mg.
There were no subjects who had the history of pre-
medication with CAM before diagnosis as pulmonary
MAC disease.
Time course of the ratio of urinary 6βOHF/F and the
serum concentrations of drugs for the initial period of the
study (days 1–29)
The mean ratio of 6βOHF/F, a marker for activity of
CYP3A4, significantly increased from 2.63 ± 0.85 (n = 9)
on the first day, to 6.96 ± 1.35 (2.6-fold) on day 15, and
7.46 ± 1.21 (2.8-fold) on day 29 (Fig. 1). The concentration
of CAM in the serum significantly decreased to approxi-
mately 30 % of the initial value, from 2.28 ± 0.61 μg/mL
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on the first day to 0.73 ± 0.23 μg/mL on day 15, and did
not notably decrease thereafter (day 29: 0.55 ± 0.22 μg/mL).
The concentration of M-5 in the serum increased 2.4-fold,
from 0.69 ± 0.15 μg/mL on the first day to 1.66 ±
0.38 μg/mL on day 15, and 1.9-fold on day 29 (1.28 ±
0.38 μg/mL). Serum RFP concentrations did not alter
(around 10 μg/mL) up to day 29, and the concentra-
tions of DR were approximately one-tenth of the RFP
concentration (Fig. 2).
Time course of the ratio of urinary 6βOHF/F and the
concentrations of drugs in the serum in the long-term
(days 1–365)
The mean 6βOHF/F ratio of four subjects who contin-
ued in this study for 1 year increased from 2.57 ± 0.61
on the first day to 3.4 times this amount on day 15, and
maintained values more than double the initial value
thereafter (Fig. 3). The concentration of CAM in the
serum decreased dramatically to approximately 40 % of
the initial value, from 2.18 ± 1.10 μg/mL on the first day to
0.80 ± 0.40 μg/mL on day 15, and remained constant until
day 365. Serum M-5 concentration increased 2.7-fold,
from 0.66 ± 0.31 μg/mL on the first day to 1.80 ±
0.75 μg/mL on day 15, and maintained consistently high
values from day 29 to the end of the study. The mean of
serum RFP concentrations were in the range from 5.88
to 11.3 μg/mL (Fig. 4). At each point, the serum DR
concentration was approximately one-tenth of the RFP
concentration. The relationship between the ratio of
urinary 6βOHF/F and serum RFP concentrations was
poor (r = – 0.295, Fig. 5).
Clinical outcomes by examination of sputum cultures and
chest images
The sputum cultures of three out of four subjects con-
verted to negative (subject B; day 29, subject C; day 57,
and subject E; day 225), whereas the cultures of one sub-
ject remained positive (Table 2). Relapse, however, oc-
curred in all the three subjects with negative sputum
cultures (subject C; on day 225, and subjects B and E;







A female 68 58 M.avium 800 600 750
B male 70 64 M.avium 800 450 750
C female 68 43 M.avium 600 450 500
D female 64 42 M.avium 800 450 500
E female 50 51 M.intracellulare 800 450 750
F female 63 47 M.avium 800 450 750
G female 70 56 M.avium 800 600 750
H female 71 48 M.avium 800 450 750
I male 75 47 M.avium and M.intracellulare 800 450 750
Fig. 1 Relationship between CYP3A4 activity and serum clarithromycin
or its metabolite concentrations for the initial period. Time course of
serum concentrations of clarithromycin (CAM, ○), 14-hydroxy-CAM
(M-5, △), and urinary 6β-hydroxycortisol/cortisol (6βOHF/F, ♦) ratio up
to day 29 (n = 9, mean ± SE). *P <0.05 compared with each initial value
Fig. 2 Relationship between CYP3A4 activity and serum rifampicin or
its metabolite concentrations for the initial period. Time course of
serum concentrations of rifampicin (RFP, □) and 25-desacetyl-RFP (DR, ◊),
and the ratio of urinary 6β-hydroxycortisol/cortisol (6βOHF/F, ♦) up to
day 29 (n= 9, mean ± SE). *P< 0.05 compared with each initial value
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after day 365). The chest images of the 4 subjects rarely
worsened, but generally showed a slight improvement.
CAM susceptibility test
The MIC values are shown in Table 2. CAM-resistant
MAC isolates were not detected in the subjects who were
examined using the CAM susceptibility test in this study.
Discussion
This is the first study to investigate the long-term changes
in the serum concentrations of CAM, RFP, and their
metabolites in pulmonary MAC disease patients and to
examine the correlation of these concentrations with the
ratio of urinary 6βOHF/F and clinical outcomes.
Our results in the initial stage of treatment (days 1–29)
showed a remarkable decrease in serum CAM concentra-
tions with a change from baseline in accordance with an
earlier report [4, 5]. This study succeeded in clarifying that
CAM concentration in the serum decreased significantly
by day 15, whereas the ratio of 6βOHF/F and serum M-5
concentration increased over the same period of time
(Fig. 1). This was not measured in the previous studies.
This increased metabolism from CAM to M-5 resulted
from the induction of the enzyme, CYP3A4 by RFP. Al-
though there was a 2-to 4-fold variation in the mean of
6βOHF/F over the extended period of the study (days
1–365), after day 15, the decrease in serum CAM con-
centrations and the increase in serum M-5 concentra-
tions were maintained consistently throughout the
study period (Fig. 3). These findings suggest that serum
CAM and M-5 concentrations were maintained at
their new levels if the induction of CYP3A4 reached a
certain point (more than double of the initial value in
this study).
On the other hand, CYP3A4 hardly affects the metab-
olism of RFP because the main metabolic pathway of
Fig. 3 Long-term changes of CYP3A4 activity and serum clarithromycin or its metabolite concentrations. Time course of serum concentration of
clarithromycin (CAM, ○) and 14-hydroxy-CAM (M-5, △), and the ratio of urinary 6β-hydroxycortisol/cortisol (6βOHF/F, ♦) up to the day 365
(n = 4, mean ± SE)
Fig. 4 Long-term changes of CYP3A4 activity and serum rifampicin or its metabolite concentrations. Time course of serum concentration of
rifampicin (RFP, □) and 25-desacetyl-RFP (DR, ◊), and ratio of urinary 6β-hydroxycortisol/cortisol (6βOHF/F, ♦) up to day 365 (n = 4, mean ± SE)
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RFP is deacetylation to 25-desacetylrifampicin (DR) by
arylacetamide deacetylase [11]. In subjects with tubercu-
losis, receiving daily doses of RFP, the serum RFP concen-
trations increased after the first dose, decreased during the
first month, and remained constant without a significant
decrease thereafter [17, 18]. Serum RFP concentrations
were reportedly lower in patients with tuberculosis who re-
ceived repeated RFP administrations than that in healthy
adults or in patients receiving this therapy for the first time.
It was suggested that these results were a consequence of
RFP-mediated induction of the enzyme involved in the
biliary excretion [17]. In the present study however, all the
subjects were diagnosed with pulmonary MAC disease, and
all of them received CAM in addition to RFP. CAM is
known to behave as a motilin agonist with gastrointestinal
motor-stimulating activity resulting in an increase in
gastric emptying rate [19], thereby antagonizing the effect
of p-glycoprotein in the gastrointestinal tract or kidney [8]
and CYP3A4 in the intestine or liver [9]. These effects of
CAM are thought to increase the serum concentration of
concomitantly administered drugs. Therefore, these effects
might have led to the partial alteration of serum RFP con-
centrations in this study.
Alffenaar and colleagues [10] collected plasma samples
at nine points per day eight weeks after the beginning of
the therapy and demonstrated that total RFP exposure
increased in patients receiving CAM compared to that
in patients receiving RFP without CAM (1.2-fold in
maximum drug concentration and 1.6-fold in area under
the plasma concentration curve). They speculated that
CAM inhibitory effects on the p-glycoprotein-mediated
efflux of RFP were responsible. Although serum RFP con-
centration increased on some observation day in our study,
we could not calculate the maximum drug concentration
and area under the concentration curve because serum
RFP concentration was measured only once on each exam-
ination day in this study. Therefore, we were not able to
compare our results with theirs. However, interestingly, the
serum RFP concentration and urinary 6βOHF/F ratio often
intersected with each other. When the serum RFP concen-
tration was high, the urinary 6βOHF/F ratio was low, and
vice versa. We examined the relationship between the ratio
of urinary 6βOHF/F and serum RFP concentrations and
found a poor correlation (Fig. 5), suggesting that the serum
RFP concentration was not directly affected by the level of
CYP3A4 induction. Since it was reported that 450 mg of
RFP a day achieved maximum induction of enzyme [20],
the dose of RFP administered to subjects in this study
should have been sufficient for maximum induction of
CYP3A4. Accordingly, even if the serum RFP concentra-
tions varied to some extent, RFP-mediated CYP3A4 induc-
tion would have been expected to reach the maximum by
day 15 and remain high, explaining the consistently low
serum CAM concentrations in the study subjects with pul-
monary MAC disease despite the administration of recom-
mended standard treatment.
Currently, the bacilli negative conversion rates of the
standard treatment for pulmonary MAC disease have
been reported to be approximately 60–80 % [21–25],
with relapse occurring in 48 % of patients after comple-
tion of treatment [26]. Therefore, this disease is often
difficult to treat. In our study, the sputum cultures of
three out of four subjects converted to negative, but re-
lapse occurred in all three cases (Table 2). All three sub-
jects whose sputum culture conversion was not achieved
after 169 days (subject C, D, and E) remained susceptible
to CAM on the testing day. The decreased CAM con-
centrations in each patient were generally higher than
MICs for MAC isolated from each patient. However,
predicting the clinical efficacy by direct comparison with
the drug concentration is difficult because MIC means
the minimal drug concentration to inhibit growth of
bacteria in vitro. MAC originally colonizes the airways,
and then infects the epithelial cells and macrophages
[27], suggesting that the concentrations of antimicrobials
in epithelial lining fluid (ELF) in lungs are an important
factor in its suppression. The CAM concentration in the
extracellular fluid to exhibit the efficacy against MAC
has been reported to be 1–8 μg/mL [5, 28–30]. Hase-
gawa and colleagues [30] demonstrated that the ELF/
serum CAM concentration ratio in patients treated with
400 or 800 mg/day of CAM was highly individual and
ranged between 2.0 and 41.5. Although they concluded
that 800 mg/day of CAM administration was an appro-
priate dose because the mean ELF concentration of
CAM was ≧8 μg/mL, the individual ELF concentration
of CAM in some subjects was less than this target value.
Moreover, clinical outcomes were not examined. Based on
Fig. 5 Relationship between CYP3A4 activity and serum rifampicin
concentration in the long-term. Relationships between the ratio of
urinary 6β-hydroxycortisol/cortisol (6βOHF/F) and serum concentrations
of rifampicin (RFP). Symbols represent values on days 1 to 365
(n = 4, mean ± SE)
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Table 2 Clinical efficacy of treatment for pulmonary Mycobacterium avium complex patients




1 29 57 85 113 141 169 225 281 337 365 Remarks
B Sputum culture 1+ – a – – – – – – – – – No data Relapsed at day 553
Chest image Unchanged Unchanged Unchanged Improved Unchanged Unchanged Unchanged Unchanged Unchanged Improved
C Sputum culture 1+ 1+ – a – – – No data 1+ b – 1+ 1+ 0.06
Chest image Unchanged Unchanged Improved Unchanged Unchanged Unchanged Unchanged Unchanged Unchanged Unchanged (Day 365)
D Sputum culture 1+ 1+ 1+ – 1+ 1+ 1+ 1+ 1+ 1+ 1+ 0.25
Chest image Unchanged Unchanged Improved Unchanged Unchanged Unchanged Unchanged Unchanged Unchanged Unchanged (Day 365)
E Sputum culture – 1+ – 1+ – 1+ 1+ – a – – – 0.06 Relapsed at day 589
Chest image Improved Unchanged Improved Unchanged Worsened Improved Unchanged Unchanged Unchanged Unchanged (Day 169)
MIC; Minimal inhibitory concentrations, CAM; Clarithromycin
aCulture negative conversion: the first day of three consecutive negative cultures

















the decreased concentrations of CAM (0.36–0.80 μg/mL)
in this study, it seemed likely that the ELF concentrations
of CAM in some subjects who presented poor CAM per-
meability into the ELF were insufficient and resulted in
unfavorable clinical outcomes.
Kobashi and colleagues [31] compared the clinical out-
comes of subjects with pulmonary MAC disease who re-
ceived CAM 400–600 mg and 800 mg. According to
their results, the bacilli negative conversion rate for the
treatments was 69 and 84 %, respectively. Koga and col-
leagues [32] reported that the serum CAM concentra-
tions in patients with chronic respiratory infection who
received CAM 150–200 mg/day were 1.31–3.45 μg/mL at
1–3 h after administration. Our results (0.36–0.80 μg/mL)
after day 15 were lower than those previously reported,
probably due to maximum induction of CYP3A4. In some
countries, 1000 mg/day of CAM have been commonly
administered to pulmonary MAC disease patients [33]
and our findings suggest that increasing the dose of CAM
over the standard treatment may improve the clinical out-
comes. Kawai [34] insisted that the dosage of prednisolone
should be doubled to maintain efficacy when used in con-
junction with RFP. Matsui and colleagues [35] proposed
that, when administered in conjunction with RFP, it was
appropriate to increase the dosage of cyclosporine by ap-
proximately 3 times within the first 2 weeks, and that
long-term frequent measurements of trough level and
dose adjustment were required. Based on these reports, it
seems likely that the unsatisfactory clinical outcomes in
MAC may be attributed to continuously low serum con-
centrations of CAM and it may be beneficial to reassess
the maximum dose of CAM in Japan (800 mg/day), and
introduce stepwise administration of CAM for the treat-
ment of pulmonary MAC disease.
Our study has several limitations. First, this study was
conducted at a single center. Therefore, the number of
subjects was limited. Especially, there were only four sub-
jects who could be followed for 1 year. Secondly, all sub-
jects were outpatients and the severity was mild. Finally,
blood samples were collected only after two hours of drug
administration on each consultation day. Although more
subject data will be needed to verify the correlation be-
tween serum CAM concentration and clinical outcomes,
we believe that long-term monitoring of CAM is benefi-
cial for therapeutic drug treatment of patients with unsat-
isfactory clinical outcomes. Increasing the dosage of CAM
may improve the outcomes for patients with a poor clin-
ical response to long-term treatment due to low serum
concentrations of drug. It may also be useful to decrease
the dosage of RFP to a point where efficacy is retained but
there is less influence on the induction of CYP3A4. This
study provides the first step in the design of a new plan
for drug administration appropriate for the treatment of
pulmonary MAC disease.
Conclusions
Our study demonstrated consistently low levels of serum
CAM due to RFP-mediated induction of CYP3A4 in pul-
monary MAC disease patients treated with a standard com-
bination of CAM and RFP. These continuously low
concentrations of CAM are suggested to be responsible for
unsatisfactory clinical outcomes of this disease.
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